The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The main purpose of this exploratory study was to investigate the instant efficacy and safety of alverine oral administration in decreasing portal hypertension. Condition of disease: Cirrhotic portal hypertension Intervention/treatment: Drug: Alverine 60 mg (1 capsule), orally Drug: Alverine 120 mg (2 capsules), orally
Epistemonikos ID: 8323918f66f2dd8a3ec29bb5bf4d9db5704db51b
First added on: May 13, 2024